I mean, why would any company with no current revenues want to get approval for their drug in a country of 1.4B people currently in the middle of an outbreak!?! It's not like other companies are flocking there and have received expedited approval and are making money right!?! MF must be really desperate to seek opportunities elsewhere while our FDA trial continues with primary endpoint and completion dates in JULY and AUGUST respectively!
In case you missed it I was being sarcastic above. Just noting how silly your points are and how they fall apart with minimal examination. As I stated above, India is in dire need of treatments hence the slew of companies seeking and having received approval so far....that translates into $$ for Revive. How stupid would it be for a CEO to disregard such an opportunity to generate revenue, especially since we already have months of FDA approved data that could possibly be presented to the Indian authorities. As for the FDA, last I checked we are still almost 6 weeks away from the primary endpoint so to claim that avenue is somehow invalidated is premature and again, silly.
You critique those of us who are bullish on RVV as being ""biased"" yet fail to see your own clear ""bias"" re everything RVV which is demonstrated in virtually every one of your posts. I think they call that hypocrisy!!!
NOTE: Can't prove it of course but I strongly suspect the main reason for our seemingly exaggerated pps stagnation of late is our most recent investor whose name starts with C.
